Lancet[journal] 检索结果

81. Traditional Chinese medicine for acute intracerebral haemorrhage.

作者: Yuhan Chen.;Xinning Liang.;Zhaolan Liu.
来源: Lancet. 2025年405卷10491期1741页

82. Traditional Chinese medicine for acute intracerebral haemorrhage.

作者: Xiaolong Xu.;Huahao Fan.;Qingquan Liu.
来源: Lancet. 2025年405卷10491期1740页

83. Traditional Chinese medicine for acute intracerebral haemorrhage.

作者: Fengjun Zhang.;Zhe Wang.;Wencheng Kong.;Wei Zhang.;Tao Wang.
来源: Lancet. 2025年405卷10491期1739页

84. Traditional Chinese medicine for acute intracerebral haemorrhage.

作者: Yanchen Zhu.;Jiqiang Hu.;Shaozhen Ji.;Mingkai Huang.
来源: Lancet. 2025年405卷10491期1739-1740页

85. Traditional Chinese medicine for acute intracerebral haemorrhage.

作者: Arthur Yin Fan.;Sherman Gu.;Changzhen Gong.
来源: Lancet. 2025年405卷10491期1738页

86. Traditional Chinese medicine for acute intracerebral haemorrhage.

作者: Hongbo Jia.;Wei Liu.;Xiaonong Fan.;Yibing Li.;Li Li.
来源: Lancet. 2025年405卷10491期1738-1739页

87. Traditional Chinese medicine for acute intracerebral haemorrhage.

作者: Renqi Luo.;Hui Hui.;Haodong Ge.;Xue Ran.
来源: Lancet. 2025年405卷10491期1737-1738页

88. Trump vs higher education: stifling American innovation.

作者: The Lancet.
来源: Lancet. 2025年405卷10491期1717页

89. Regulatory asymmetry in Alzheimer's disease care.

作者: Juan Fortea.;Marina Boban.;Sebastiaan Engelborghs.;Kristian Steen Frederiksen.;Jakub Hort.;Sean Kennelly.;Milica Gregoric Kramberger.;Shima Mehrabian.;Domenico Plantone.;Claire Paquet.;Isabel Santana.;Nikolaos Scarmeas.;Eino Solje.;Luiza Spiru.;Stanislav Šutovský.;Everard G B Vijverberg.;Bengt Winblad.;Frank Jessen.
来源: Lancet. 2025年405卷10492期1812-1813页

90. Africa's renaissance amid declining overseas health aid.

作者: Nelson K Sewankambo.;Hossein Akbarialiabad.;Serigne Magueye Gueye.;Sabrina Bakeera-Kitaka.;Judy N Khanyola.;Kiguli-Malwadde Elsie.;Chiratidzo E Ndhlovu.;Bruce Kirenga.;Abigail Kazembe.;Prisca Olabisi Adejumo.;Majid Sadigh.;Mosa Moshabela.
来源: Lancet. 2025年

91. Freezing of USAID: a health crisis for India's transgender community.

作者: Shashwat S Banerjee.;Barnali Goswami Banerjee.
来源: Lancet. 2025年405卷10492期1813-1814页

92. Guatemala's resolution on kidney health: a historic opportunity.

作者: Marcello Tonelli.;Masaomi Nangaku.;Magdalena Machalska.;Agnes Fogo.;Vivekanand Jha.;David Harris.;Adeera Levin.;Giuseppe Remuzzi.
来源: Lancet. 2025年405卷10492期1809-1810页

93. Examining the evidence for IL-2 in amyotrophic lateral sclerosis.

作者: Michael Benatar.;Michael P McDermott.
来源: Lancet. 2025年405卷10492期1793-1795页

94. Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.

作者: Gilbert Bensimon.;P Nigel Leigh.;Timothy Tree.;Andrea Malaspina.;Christine Am Payan.;Hang-Phuong Pham.;Pieter Klaassen.;Pamela J Shaw.;Ahmad Al Khleifat.;Maria D M Amador.;Shahram Attarian.;Simon M Bell.;Stéphane Beltran.;Emilien Bernard.;William Camu.;Philippe Corcia.;Jean-Christophe Corvol.;Philippe Couratier.;Véronique Danel.;Rabab Debs.;Claude Desnuelle.;Aikaterini Dimitriou.;John Ealing.;Florence Esselin.;Marie-Céline Fleury.;George H Gorrie.;Aude-Marie Grapperon.;Adèle Hesters.;Raul Juntas-Morales.;Ivan Kolev.;Géraldine Lautrette.;Nadine Le Forestier.;Christopher J McDermott.;Nicolas Pageot.;François Salachas.;Nikhil Sharma.;Marie-Hélène Soriani.;Jemeen Sreedharan.;Juliette Svahn.;Nick Verber.;Annie Verschueren.;Ozlem Yildiz.;Carey M Suehs.;Safaa Saker-Delye.;Claudie Muller.;Christophe Masseguin.;Hana Hajduchova.;Janine Kirby.;Cecilia Garlanda.;Massimo Locati.;Henrik Zetterberg.;Bernard Asselain.;Ammar Al-Chalabi.; .
来源: Lancet. 2025年405卷10492期1837-1850页

Amyotrophic lateral sclerosis (ALS) is a life-threatening disease characterised by progressive loss of motor neurons with few therapeutic options. The MIROCALS study tested the hypothesis that low-dose interleukin-2 (IL-2LD) improves survival and function in ALS.

95. Reducing the burden of chronic kidney disease in the world.

作者: Randall Lou-Meda.;Joaquín Barnoya Pérez.
来源: Lancet. 2025年405卷10492期1810页

96. Nivolumab plus ipilimumab in hepatocellular carcinoma.

作者: Mathew Vithayathil.;Rohini Sharma.
来源: Lancet. 2025年405卷10492期1795-1797页

97. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.

作者: Thomas Yau.;Peter R Galle.;Thomas Decaens.;Bruno Sangro.;Shukui Qin.;Leonardo G da Fonseca.;Hatim Karachiwala.;Jean-Frederic Blanc.;Joong-Won Park.;Edward Gane.;Matthias Pinter.;Ana Matilla Peña.;Masafumi Ikeda.;David Tai.;Armando Santoro.;Gonzalo Pizarro.;Chang-Fang Chiu.;Michael Schenker.;Aiwu He.;Hong Jae Chon.;Joanna Wojcik-Tomaszewska.;Gontran Verset.;Qi Qi Wang.;Caitlyn Stromko.;Jaclyn Neely.;Prianka Singh.;Maria Jesus Jimenez Exposito.;Masatoshi Kudo.; .
来源: Lancet. 2025年405卷10492期1851-1864页

Patients with unresectable hepatocellular carcinoma have a poor prognosis, and treatments with long-term benefits are needed. We report results from the preplanned interim analysis of the CheckMate 9DW trial assessing nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma in the first-line setting.

98. Department of Error.

来源: Lancet. 2025年405卷10490期1665页

99. Isotretinoin-associated cervical osteophytosis - Authors' reply.

作者: Kamran Naraghi.;Helena Marzo-Ortega.
来源: Lancet. 2025年405卷10490期1664-1665页

100. Isotretinoin-associated cervical osteophytosis.

作者: Huang Chang-Quan.
来源: Lancet. 2025年405卷10490期1664页

结果排序

文献格式

出版时间

出版类型

出版语言